We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    nifurtimox and medulloblastoma
Previous Study | Return to List | Next Study

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

This study is currently recruiting participants.
Verified April 2017 by Giselle Sholler, Spectrum Health Hospitals
Sponsor:
ClinicalTrials.gov Identifier:
NCT00601003
First Posted: January 25, 2008
Last Update Posted: April 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Bayer
Information provided by (Responsible Party):
Giselle Sholler, Spectrum Health Hospitals
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2020
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)